# Se-Methyl-Seleno-L- Cysteine (MSC) in Treating Healthy Patients

> **NCT00489372** · PHASE1 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 36 (actual)

## Conditions studied

- Healthy, no Evidence of Disease

## Interventions

- **DRUG:** Se-methyl-seleno-L-cysteine
- **OTHER:** placebo
- **OTHER:** pharmacological study
- **OTHER:** laboratory biomarker analysis

## Key facts

- **NCT ID:** NCT00489372
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-07
- **Primary completion:** 2008-03
- **Final completion:** 2009-07
- **Target enrollment:** 36 (ACTUAL)
- **Last updated:** 2014-11-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00489372

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00489372, "Se-Methyl-Seleno-L- Cysteine (MSC) in Treating Healthy Patients". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT00489372. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*